arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

Vistagen Therapeutics, Inc.

VTGN
$0.29 ▲ +0.01 (+3.20%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vistagen Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.0M
Dividend Yield
Revenue Growth 161.1%
Op. Margin None
ROIC -203.1%
FCF / Share $-1.74
Trailing P/E
Price / Book 0.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

28-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.27M
↑ +161.1%
Net Income Profit after all expenses
$-69.69M
↓ -35.5%
Operating Margin Operating profit as % of sales
-344.6%
↓ -8.7%
FCF / Share Free cash flow per share
$-1.74
↓ -28.0%
Long-Term Debt Long-term obligations
$58.80K
↓ -97.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
2
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 28 years · 77 quarters